Cover Image
市場調查報告書

血友病治療藥的全球市場

Global Haemophilia Therapeutics Market

出版商 Frost & Sullivan 商品編碼 328326
出版日期 內容資訊 英文 105 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血友病治療藥的全球市場 Global Haemophilia Therapeutics Market
出版日期: 2015年04月09日 內容資訊: 英文 105 Pages
簡介

一般認為基因改造療法和預防療法的利用擴大,將會促進血友病的治療藥市場成長。

本報告提供全球血友病治療藥 (特別是通過FDA (聯邦食品藥品管理局) 認證的產品,及臨床實驗最後階段的產品) 之市場相關分析,提供您血友病的患病人數·發病率趨勢,及臨床實驗中的開發中產品一覽,今後的技術開發·產品上市預測等調查、考察。

第1章 摘要整理

第2章 簡介

  • 簡介
  • 血友病的分類
  • 血友病治療的指南:預防/隨選
  • 市場概要:區分

第3章 流行病學與患者數預測

  • 血友病:患病人數與發病率
  • 血友病:全球的盛行率·治療率

第4章 市場趨勢與收益額預測

  • 預測的前提條件與定義
  • 血友病治療市場:收益額的預測
  • 基因改造療法·預防治療的利用增加
  • 預防治療的實施情形:各地區的差異
  • 血友病的年度轉換率
  • A型血友病/類血友病病 (vWD) 治療藥市場收益額預測
  • B型血友病治療藥市場收益額預測
  • 抑制劑 (繞道止血劑) 市場收益額預測

第5章 已上市產品分析

  • 第八凝血因子 (A型血友病) 及第八凝血因子/Von Willebrand' s因子 (vWD)
  • 第九凝血因子 (B型血友病)
  • 第VIIa因素 (抑制劑)

第6章 開發中產品分析

  • 血友病治療藥:開發中產品的競爭環境
  • 血友病治療藥:開發平台分析
  • 第八凝血因子 (A型血友病) 及第八凝血因子/Von Willebrand' s因子 (vWD)
  • 第九凝血因子 (B型血友病)
  • 第VIIa因素 (抑制劑)

第7章 臨床上主要的里程碑

  • 血友病治療藥市場:臨床上主要的里程碑
  • 血友病治療藥市場:進展中/近來完成的主要臨床實驗

第8章 近來通過認證的/臨床實驗最後階段的開發平台治療藥候補一覽

  • Eloctate (Biogen Idec/SOBI)
  • NovoEight (Turoctocog alfa) (Novo Nordisk)
  • BAX 111 (Baxter)
  • BAX 855 (Baxter)
  • BAY81-8973 (Bayer)
  • Nuwiq/Human-cl rhFVIII (simotocog alfa) (Octapharma)
  • BAY94-9027 (Bayer)
  • N8-GP (turoctocog alfa pegol) (Novo Nordisk)
  • rVIII-Single Chain (CSL Behring)
  • Alprolix (Biogen Idec/SOBI)
  • Rixubis (Baxter)
  • rIX-FP (CSL Behring)
  • IB1001-Cangene (Emergent Biosolutions)
  • N9-GP (nonacog beta pegol) (Novo Nordisk)
  • Obizur (Baxter)
  • BAX 817 (Baxter)
  • LR769 (rEVO Biologics/LFB)

第9章 未來的治療方法和關係到延命治療的新技術

  • 與延命治療相關的新技術:凝血因子濃縮劑
  • 新開發平台療法:遺傳基因療法
  • 新開發平台療法:RNA干擾法
  • 新開發平台療法:組織因素途徑抑制劑

第10章 市場主要趨勢的時間軸

  • A型血友病治療藥 (FVIII) 市場的情況
  • B型血友病治療藥 (FIX) 市場的情況
  • 抑制劑 (繞道止血劑) (FVIIa) 市場的情況

第11章 值得注意的主要企業

  • SWOT分析:Bayer
  • SWOT分析: Baxter
  • SWOT分析:Novo Nordisk
  • SWOT分析:Pfizer
  • SWOT分析:Biogen Idec
  • SWOT分析:CSL Behring
  • 主要企業的產品比較分析

第12章 結論

第13章 附錄

第14章 關於FROST & SULLIVAN

目錄
Product Code: MAD9-01-00-00-00

Increased Use of Recombinant and Prophylaxis Therapies Drives Growth

This research service focuses on the global haemophilia therapeutics market, with a particular focus on recently FDA-approved drugs and late-stage compounds for the treatment of haemophilia A, haemophilia B, inhibitors, and von Willebrand Disease. Pipeline analysis outlines the major FDA-approved haemophilia products, which include those submitted for regulatory review and those in Phase I, II, and III of clinical development. The study also provides an overview of the major clinical trials of recently approved or late-stage pipeline candidates. Novel technologies to extend product half-life and potential future therapies for haemophilia patients have also been discussed.

Table of Contents

1. EXECUTIVE SUMMARY

  • 1. Executive Summary-Key Findings
  • 2. Executive Summary-Key Findings (continued)
  • 3. Haemophilia Drugs Market-Game-changing Strategies
  • 4. Key Merger, Acquisition, and Partnership Assessment
  • 5. Key Merger, Acquisition, and Partnership Assessment (continued)
  • 6. Methodology and Scope

2. INTRODUCTION

  • 1. Introduction
  • 2. Introduction (continued)
  • 3. Classification of Haemophilia
  • 4. Treatment Guidelines for Haemophilia Therapy-Prophylactic or On-demand
  • 5. Market Overview-Segmentation
  • 6. Market Overview-Segmentation (continued)

3. HAEMOPHILIA THERAPEUTICS MARKET-EPIDEMIOLOGY AND PATIENT FORECASTS

  • 1. Haemophilia-Prevalence and Incidence
  • 2. Haemophilia-Global Prevalence and Treatment Rates

4. HAEMOPHILIA THERAPEUTICS MARKET-TRENDS AND REVENUE FORECASTS

  • 1. Forecast Assumptions and Definitions
  • 2. Haemophilia Therapeutics Market-Revenue Forecast
  • 3. Revenue Forecast Discussion
  • 4. Revenue Forecast Discussion (continued)
  • 5. Increasing Use of Recombinant and Prophylactic Treatment
  • 6. Variation in Adoption of Prophylactic Therapy by Region
  • 7. Annual Switching Rates in Haemophilia
  • 8. Global Haemophilia A and vWD Therapeutics Market Revenue Forecast
  • 9. Revenue Forecast Discussion
  • 10. Revenue Forecast Discussion (continued)
  • 11. Haemophilia B Therapeutics Market-Revenue Forecast
  • 12. Revenue Forecast Discussion
  • 13. Revenue Forecast Discussion (continued)
  • 14. Inhibitors (Bypassing Agents) Market-Revenue Forecast
  • 15. Revenue Forecast Discussion
  • 16. Revenue Forecast Discussion (continued)

5. HAEMOPHILIA THERAPEUTICS MARKET-MARKETED PRODUCT ANALYSIS

  • 1. Product Analysis-F VIII (Haemophilia A) and FVIII/vWF (vWD)
  • 2. Product Analysis-F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)
  • 3. Product Analysis-F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)
  • 4. Product Analysis-F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)
  • 5. Product Analysis-Factor IX (Haemophilia B)
  • 6. Product Analysis-Factor IX (Haemophilia B) (continued)
  • 7. Product Analysis-Factor VIIa (Inhibitors)

6. HAEMOPHILIA THERAPEUTICS MARKET-PIPELINE ANALYSIS

  • 1. Haemophilia Drugs-Competitive Landscape of Products in Development
  • 2. Haematological Drugs-Pipeline Analysis
  • 3. Pipeline Analysis-F VIII (Haemophilia A) and FVIII/VWF (VWD)
  • 4. Pipeline Analysis-F IX (Haemophilia B)
  • 5. Pipeline Analysis-F VIIa (Inhibitors)

7. HAEMOPHILIA THERAPEUTICS MARKET-MAJOR CLINICAL MILESTONES

  • Haemophilia Therapeutics Market-Major Clinical Milestones
  • 1. Haemophilia Therapeutics Market-Major Ongoing/Recently Completed Clinical Trials
  • 2. Haemophilia Therapeutics Market-Major Ongoing/Recently Completed Clinical Trials (continued)
  • 3. Haemophilia Therapeutics Market-Major Ongoing/Recently Completed Clinical Trials (continued)

8. HAEMOPHILIA THERAPEUTICS MARKET-PRODUCT DASHBOARD OF RECENTLY APPROVED AND LATE-STAGE PIPELINE DRUG CANDIDATES

  • 1. Eloctate-Biogen Idec/SOBI
  • 2. NovoEight (Turoctocog alfa)-Novo Nordisk
  • 3. BAX 111-Baxter
  • 4. BAX 855-Baxter
  • 5. BAY81-8973-Bayer
  • 6. Nuwiq/Human-cl rhFVIII (simotocog alfa)-Octapharma
  • 7. BAY94-9027-Bayer
  • 8. N8-GP (turoctocog alfa pegol)-Novo Nordisk
  • 9. rVIII-Single Chain-CSL Behring
  • 10. Alprolix-Biogen Idec/SOBI
  • 11. Rixubis-Baxter
  • 12. rIX-FP-CSL Behring
  • 13. IB1001-Cangene (Emergent Biosolutions)
  • 14. N9-GP (nonacog beta pegol)-Novo Nordisk
  • 15. Obizur-Baxter
  • 16. BAX 817-Baxter
  • 17. LR769-rEVO Biologics/LFB

9. HAEMOPHILIA THERAPEUTICS MARKET-FUTURE THERAPIES AND NOVEL TECHNOLOGIES TO EXTEND HALF-LIFE

  • 1. Novel Technologies that Extend Half-life of Factor Concentrates
  • 2. Novel Technologies that Extend Half-life of Factor Concentrates (continued)
  • 3. Novel Technologies that Extend Half-life of Factor Concentrates (continued)
  • 4. Novel Technologies that Extend Half-life of Factor Concentrates (continued)
  • 5. Novel Pipeline Therapies-Gene Therapy
  • 6. Novel Pipeline Therapies-RNA Interference
  • 7. Novel Pipeline Therapies-Tissue Factor Pathway Inhibitor

10. HAEMOPHILIA THERAPEUTICS MARKET-TIMELINE OF KEY EVENTS

  • 1. Haemophilia A Therapeutics (FVIII) Market-Timeline of Key Events
  • 2. Haemophilia B Therapeutics (FIX) Market-Timeline of Key Events
  • 3. Inhibitors (Bypassing Agents) (FVIIa) Market-Timeline of Key Events

11. HAEMOPHILIA THERAPEUTICS MARKET-KEY COMPANIES TO WATCH

  • 1. Leading Big Pharma Companies-SWOT Analysis Bayer
  • 2. Leading Big Pharma Companies-SWOT Analysis Baxter
  • 3. Leading Big Pharma Companies-SWOT Analysis Novo Nordisk
  • 4. Leading Big Pharma Companies-SWOT Analysis Pfizer
  • 5. Key Companies to Watch-SWOT Analysis Biogen Idec
  • 6. Key Companies to Watch-SWOT Analysis CSL Behring
  • 7. Comparative Product Analysis of Key Market Participants

12. CONCLUSIONS

  • 1. Conclusions and Recommendations
  • 2. Legal Disclaimer

13. APPENDIX

  • 1. List of Abbreviations

14. THE FROST & SULLIVAN STORY

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top